Benzene and Acute Myeloid Leukemia: A Clinical Evidence Review
From General Health Awareness to Occupational Concern
The legacy of general health and science information has long provided a foundational understanding of environmental factors that may influence human well-being. Within this broad context, public health guidance has historically emphasized the importance of recognizing potential hazards in everyday settings, from household products to ambient air quality. This heritage of awareness naturally extends into more specialized domains where exposure risks are elevated, particularly in occupational environments. As workers in industrial sectors encounter substances at higher concentrations than the general population, the transition from general health principles to focused occupational concern becomes a logical progression. Among the many chemical agents studied in workplace settings, benzene has drawn particular attention due to its widespread use in manufacturing processes. The shift from a general health perspective to an occupational exposure concern involves examining how routine contact with such compounds in mass production settings may relate to specific health outcomes. This pivot requires careful consideration of exposure levels, duration, and patterns that distinguish workplace scenarios from community exposures. The following review addresses the clinical evidence regarding benzene and its association with acute myeloid leukemia, focusing on the occupational context where exposure concerns are most pronounced.
Benzene as a Myelotoxin and Carcinogen
Benzene is a recognized myelotoxin and carcinogen, with chronic exposure linked to an increased risk of acute myeloid leukemia (AML) and other hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279). Occupational exposure to benzene at levels of 10 parts per million (ppm) or more has been associated with a heightened risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013). The mode of action for benzene-induced AML is believed to involve multiple key events, including hematotoxicity and genetic toxicity observable in the peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013). These early events, if prevented, could avert the progression to myelodysplastic syndromes (MDS) and AML, which are apical adverse outcomes (https://pubmed.ncbi.nlm.nih.gov/33429013). Mechanistic pathways linking benzene to AML include genotoxic effects, oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279). However, genetic alterations alone may not fully explain the onset of hematologic malignancies, suggesting that epigenetic changes, such as altered gene expression, also play a role (https://pubmed.ncbi.nlm.nih.gov/34069279). This complexity underscores the need for comprehensive risk models that incorporate key event information to better predict AML risk following benzene exposure (https://pubmed.ncbi.nlm.nih.gov/33429013).
Epidemiological Evidence and Exposure-Response Relationships
Epidemiological evidence supports a causal relationship between occupational benzene exposure and AML. A study using the Swiss National Cohort found that occupational benzene exposure was associated with increased mortality from lymphohaematopoietic cancers, including AML (https://pubmed.ncbi.nlm.nih.gov/38727681). This study applied a quantitative benzene job-exposure matrix to census-reported occupations, reinforcing the link between benzene and AML in occupational settings (https://pubmed.ncbi.nlm.nih.gov/38727681). Additionally, a meta-analysis of 25 studies reported an elevated risk of childhood AML associated with benzene exposure, with an odds ratio of 1.22 per 1 μg/m³ increase in benzene concentration (95% confidence interval: 1.02–1.46) (https://pubmed.ncbi.nlm.nih.gov/41485753). This finding highlights that benzene-related AML risk extends to non-occupational, environmental exposures, including in pediatric populations. The exposure-response relationship between benzene and AML has been estimated by integrating data from human epidemiological studies, human biomarker studies, and experimental animal studies. A linear meta-regression model best predicted AML risks when combining six human AML studies, three human leukemia studies, ten human biomarker studies, and four animal studies (https://pubmed.ncbi.nlm.nih.gov/34906966). This integrated approach improves risk assessment by leveraging sparse data across the exposure range, providing a more robust basis for understanding the dose-response curve (https://pubmed.ncbi.nlm.nih.gov/34906966).
Clinical Presentation and Causation Considerations
From a clinical perspective, AML presents with symptoms related to bone marrow failure, such as fatigue, infection, and bleeding, and is diagnosed through blood counts and bone marrow examination. The timeline between benzene exposure and documented harm can vary, but occupational studies indicate that chronic exposure over months to years is typically required for AML development. The latency period may be influenced by exposure intensity and duration, with higher cumulative doses associated with shorter latencies. For affected patients, causation considerations involve documenting the history of benzene exposure, whether occupational or environmental, and correlating it with the onset of AML. Adequacy of warnings regarding benzene and AML is critical; given the established causal link, regulatory and workplace warnings should clearly communicate the risk of AML from benzene exposure, particularly at levels of 10 ppm or more. However, the evidence suggests that even lower environmental exposures, such as those from air pollution, may contribute to AML risk, as seen in childhood studies (https://pubmed.ncbi.nlm.nih.gov/41485753). Therefore, warnings should encompass both occupational and general population exposures to ensure informed risk mitigation.
Summary of Evidence and Implications
In summary, benzene is a well-established cause of AML, with mechanistic pathways involving genotoxicity, oxidative stress, and epigenetic changes. Epidemiological data confirm increased AML risk at occupational exposures of 10 ppm or more and at environmental levels in children. Risk models integrating multiple evidence bases support a linear exposure-response relationship. For affected patients, establishing causation requires careful exposure assessment, and adequate warnings should address both high-level occupational and lower-level environmental benzene exposures to prevent AML.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is the link between benzene exposure and acute myeloid leukemia?
Benzene is a recognized myelotoxin and carcinogen. Chronic exposure, especially at occupational levels of 10 ppm or more, increases the risk of developing acute myeloid leukemia (AML) through mechanisms including genotoxicity, oxidative stress, and epigenetic changes (https://pubmed.ncbi.nlm.nih.gov/34069279,https://pubmed.ncbi.nlm.nih.gov/33429013).
Can environmental benzene exposure cause AML in children?
Yes, a meta-analysis of 25 studies found an elevated risk of childhood AML associated with benzene exposure, with an odds ratio of 1.22 per 1 μg/m³ increase in benzene concentration (https://pubmed.ncbi.nlm.nih.gov/41485753). This indicates that even lower-level environmental exposures may contribute to AML risk.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.